Description: <p>Cichoric acid<br>
Product: Cichoric acid<br>
Alias: Chicoric acid; dicaffeoyltartaric acid; 2,3-O-dicaffeoyltartaric acid<br>
Source products: Echinacea purpurea, possibly chicory, lettuce, basil, dandelion, other Asteraceae/Lamiaceae plants<br>
Category: Polyphenol / caffeic acid derivative<br>
Primary use category: Anti-inflammatory / antioxidant / immune modulation / metabolic support<br>
AD relevance: Possible, indirect — mainly anti-inflammatory, antioxidant, metabolic, and neuroinflammation-adjacent mechanisms<br>
Cancer relevance: Possible preclinical only; not strong enough as a primary cancer product without specific paper support<br>
-Cichoric acid is strongly related to <a href="https://nestronics.ca/dbx/tbResList.php?qv=215">Echinacea</a> purpurea. It is one of the major caffeic-acid derivatives in echinacea and is commonly used as a quality marker for Echinacea purpurea extracts.
</p>
<p><b>Cichoric acid / Chicoric acid</b> — Cichoric acid is a naturally occurring dicaffeoyltartaric acid polyphenol, formally a hydroxycinnamic acid derivative composed of two caffeic acid units esterified to tartaric acid. It is best classified as a plant-derived phenolic acid / caffeic-acid derivative rather than a drug. Standard abbreviations include Cic, ChicA, and CA, although CA is ambiguous because it is also used for caffeic acid, chlorogenic acid, carnosic acid, and many other database entries. Major sources include Echinacea purpurea, chicory, lettuce, basil, dandelion, and other Asteraceae/Lamiaceae plants. It is commonly used as a quality-marker compound for Echinacea purpurea extracts, but its direct cancer-development status remains preclinical only.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Redox buffering and cytoprotective antioxidant signaling, including ROS scavenging and context-dependent NRF2/HO-1 activation.</li>
<li>Metabolic stress modulation through AMPK activation, mitochondrial protection, and reduced insulin/Akt/mTOR signaling in non-cancer metabolic models.</li>
<li>Anti-inflammatory and immunomodulatory effects, including cytokine modulation and macrophage / lymphocyte / NK-cell immune effects in Echinacea-derived or enriched preparations.</li>
<li>Preclinical cancer cytotoxicity through telomerase suppression, β-catenin reduction, caspase-9 activation, PARP cleavage, DNA fragmentation, and apoptosis in colorectal cancer cell models.</li>
<li>Migration and EMT-related suppression, likely involving β-catenin/ZEB1-related signaling in colorectal-cancer models, but still early and not clinically validated.</li>
<li>Neuroinflammation and amyloid-pathology modulation in Alzheimer’s disease models, including Aβ reduction, BACE1/APP lowering, L1CAM-associated synaptic marker restoration, and NRF2-linked antioxidant effects.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral systemic translation is constrained by polyphenol-type absorption, metabolism, plasma protein binding, and formulation stability. Rat PK/tissue-distribution work exists, but direct human PK data for isolated cichoric acid are limited. Echinacea extract exposure cannot be assumed to equal isolated cichoric acid exposure because alkamides, polysaccharides, glycoproteins, caftaric acid, and other constituents may drive part of the immune effect.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many mechanistic studies use low-to-high micromolar cichoric acid concentrations. These concentrations may exceed free systemic exposure achievable from ordinary oral Echinacea or food intake, especially after first-pass and microbial metabolism. Low-micromolar effects such as 5 μM otoprotection in zebrafish are more pharmacologically plausible than high-micromolar cytotoxicity screens, but human-equivalent exposure remains uncertain.</p>
<p><b>Clinical evidence status:</b> Cancer: preclinical only; no adequate human cancer trials for isolated cichoric acid. Immune / respiratory use: human evidence exists for Echinacea preparations, but not as isolated cichoric acid attribution. Alzheimer’s disease: preclinical only, with cell and animal-model support but no validated human clinical efficacy. Regulatory/deployment status: listed as a natural-health-product ingredient name by Health Canada; not an approved anticancer or AD therapeutic.</p>
<h3>Cichoric Acid Mechanistic Profile</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>ROS buffering and oxidative stress control</td>
<td>ROS ↓ or oxidative stress modulation (context-dependent)</td>
<td>ROS ↓; lipid peroxidation ↓; antioxidant defenses ↑</td>
<td>P, R</td>
<td>Redox buffering</td>
<td>Core polyphenol activity; likely contributes to anti-inflammatory, cytoprotective, and some cancer-cell stress effects.</td>
</tr>
<tr>
<td>2</td>
<td>NRF2 / HO-1 cytoprotective signaling</td>
<td>NRF2 effects uncertain; may protect some tumor contexts (context-dependent)</td>
<td>NRF2 ↑; HO-1 ↑; NQO1 ↑</td>
<td>R, G</td>
<td>Adaptive antioxidant response</td>
<td>Mechanistically relevant in normal-tissue protection and neuroprotection; not automatically favorable in established tumors because NRF2 can support therapy resistance in some cancers.</td>
</tr>
<tr>
<td>3</td>
<td>AMPK / Akt / mTOR metabolic signaling</td>
<td>Akt/mTOR ↓ may reduce growth signaling (model-dependent)</td>
<td>AMPK ↑; mitochondrial enzyme activity ↑; PGC-1α ↑; Akt/mTOR ↓</td>
<td>R, G</td>
<td>Metabolic stress adaptation</td>
<td>Strong mechanistic signal in myotube and aging/metabolic models; cancer relevance is plausible but not clinically established.</td>
</tr>
<tr>
<td>4</td>
<td>Telomerase suppression</td>
<td>Telomerase ↓ in HCT-116 colorectal cancer cells</td>
<td>Not established</td>
<td>G</td>
<td>Replicative capacity reduction</td>
<td>One of the more specific cancer mechanisms reported for cichoric acid, but evidence remains mainly in vitro.</td>
</tr>
<tr>
<td>5</td>
<td>Intrinsic apoptosis and PARP cleavage</td>
<td>DNA fragmentation ↑; caspase-9 ↑; cleaved PARP ↑; apoptosis ↑</td>
<td>Apoptosis ↓ in injury models (context-dependent)</td>
<td>G</td>
<td>Cell death induction in tumor models</td>
<td>Observed in colorectal cancer cells; selectivity and achievable systemic exposure are unresolved.</td>
</tr>
<tr>
<td>6</td>
<td>β-catenin / EMT axis</td>
<td>β-catenin ↓; ZEB1-related migration signaling ↓ (model-dependent)</td>
<td>Not established</td>
<td>G</td>
<td>Migration and proliferation restraint</td>
<td>Relevant to colorectal-cancer migration and Wnt-associated behavior, but still early-stage evidence.</td>
</tr>
<tr>
<td>7</td>
<td>NF-κB / inflammatory cytokines</td>
<td>Inflammatory survival signaling ↓ (context-dependent)</td>
<td>IL-6 ↓; IL-8 ↓; TNF ↓; IL-10 ↑ in Echinacea evidence base</td>
<td>R, G</td>
<td>Inflammation modulation</td>
<td>Most human-adjacent data come from Echinacea preparations rather than purified cichoric acid.</td>
</tr>
<tr>
<td>8</td>
<td>Innate and adaptive immune modulation</td>
<td>Indirect anticancer relevance only</td>
<td>Macrophage activity ↑; NK-cell activity ↑; CD4 / Th1 responses ↑ (extract-dependent)</td>
<td>G</td>
<td>Immune support</td>
<td>Important for Echinacea linkage; isolated cichoric acid should not be assumed to reproduce whole-extract immunology.</td>
</tr>
<tr>
<td>9</td>
<td>Mitochondrial protection</td>
<td>Mitochondrial stress modulation (model-dependent)</td>
<td>MnSOD ↑; mitochondrial enzyme activity ↑; mitochondrial oxidative damage ↓</td>
<td>R, G</td>
<td>Bioenergetic protection</td>
<td>More relevant to normal-tissue protection and neuro/metabolic models than direct cancer cytotoxicity.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>Anticancer concentrations may not be achievable in vivo</td>
<td>Short-term Echinacea safety appears acceptable; long-term isolated compound safety is less defined</td>
<td>G</td>
<td>Translation limitation</td>
<td>Bioavailability, extract standardization, enzymatic degradation during processing, and attribution to isolated cichoric acid are the main constraints.</td>
</tr>
</table>
<p><b>TSF legend:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br><br>
<p><b>Alzheimer’s disease relevance:</b> Cichoric acid has meaningful AD-preclinical relevance but no validated human AD clinical evidence. The main AD rationale is neuroinflammation and amyloid-pathology modulation rather than direct symptomatic cholinergic therapy. In animal and cellular AD models, cichoric acid has been reported to reduce Aβ burden, lower APP/BACE1 markers, improve synaptic-function markers, and activate antioxidant signaling. This supports an AD database sub-entry as preclinical / experimental, not as a clinically established intervention.</p>
<p><b>AD mechanisms (ranked):</b></p>
<ol>
<li>Aβ pathology reduction through decreased Aβ1–42, amyloid plaque burden, APP, and BACE1 in AD models.</li>
<li>L1CAM-associated restoration of synaptic-function markers including PSD-95 and synaptophysin.</li>
<li>Neuroinflammation suppression and systemic inflammation-to-brain inflammatory signaling reduction.</li>
<li>NRF2-linked antioxidant defense activation with HO-1 and NQO1 support in brain-aging models.</li>
<li>Metabolic and mitochondrial protection through AMPK/antioxidant effects, extrapolated from non-AD mechanistic models.</li>
</ol>
<p><b>Clinical evidence status:</b> AD evidence remains preclinical. No adequate human RCT evidence supports cichoric acid as an Alzheimer’s disease treatment. Translation constraints include oral exposure, blood-brain exposure, dose standardization, and uncertainty over whether whole-plant extracts reproduce isolated cichoric acid effects.</p>
<h3>Cichoric Acid Alzheimer’s Disease Mechanistic Profile</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Aβ / APP / BACE1 axis</td>
<td>Aβ1–42 ↓; plaques ↓; APP ↓; BACE1 ↓</td>
<td>G</td>
<td>Amyloid-pathology reduction</td>
<td>Reported in APPswe/Ind SH-SY5Y and 5xFAD mouse models; human translation remains unproven.</td>
</tr>
<tr>
<td>2</td>
<td>L1CAM / synaptic marker axis</td>
<td>L1CAM ↑; PSD-95 ↑; synaptophysin ↑</td>
<td>G</td>
<td>Synaptic-function support</td>
<td>L1CAM knockdown attenuated the synaptic-marker response in the reported model, making this a relatively specific AD mechanism.</td>
</tr>
<tr>
<td>3</td>
<td>Neuroinflammation</td>
<td>Neuroinflammation ↓; inflammatory cytokines ↓ (model-dependent)</td>
<td>R, G</td>
<td>Inflammatory injury reduction</td>
<td>Relevant because systemic inflammation can amplify AD-like neuroinflammation and amyloidogenesis in mouse models.</td>
</tr>
<tr>
<td>4</td>
<td>NRF2 / HO-1 / NQO1 antioxidant defense</td>
<td>NRF2 nuclear signaling ↑; HO-1 ↑; NQO1 ↑; oxidative stress ↓</td>
<td>R, G</td>
<td>Neuronal stress resilience</td>
<td>Best interpreted as cytoprotective and anti-inflammatory support, not disease-modifying clinical proof.</td>
</tr>
<tr>
<td>5</td>
<td>AMPK / mitochondrial protection</td>
<td>AMPK ↑; mitochondrial protection ↑; Akt/mTOR ↓</td>
<td>R, G</td>
<td>Metabolic resilience</td>
<td>Mechanistically plausible for AD but partly extrapolated from non-neuronal and aging/metabolic models.</td>
</tr>
<tr>
<td>6</td>
<td>Clinical Translation Constraint</td>
<td>Human efficacy unvalidated; CNS exposure uncertain</td>
<td>G</td>
<td>Evidence limitation</td>
<td>Use as an AD entry should be marked preclinical / experimental, with no implied human therapeutic efficacy.</td>
</tr>
</table>
<p><b>TSF legend:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>